Pfizer Stock: Still Priced Like It's Dead Money

During the coronavirus pandemic, investors got a little too excited about Pfizer's (NYSE: PFE) vaccine opportunity. When demand for COVID vaccines cooled off, the stock plunged. And it hasn't really gone anywhere since, still down over 50% from its 2021 high. But Pfizer isn't dead money if you have a long-term view of investing. Here's why you might still want to buy it.Pfizer is dealing with some headwinds. The drop in demand for COVID vaccines is just one example of the issues management is dealing with. Another is a series of upcoming patent cliffs, when generic competition is likely to lead to material revenue declines for some of the company's key drugs. And then there is the fact that Pfizer has yet to bring a GLP-1 weight-loss drug to market, leaving others to benefit from strong demand for such products.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool